MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma

ConclusionsOur results suggest a role of decreased MPC1 copy number segments in reducing overall survival in glioblastoma. MPC1 deletion is associated with poor response to TMZ chemotherapy in GBM.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 13 September 2019Source: International Journal of PharmaceuticsAuthor(s): Jieying Cai, Shiwen Luo, Xueli Lv, Yingguang Deng, Hongyuan Huang, Boxin Zhao, Qing Zhang, Guofeng LiAbstractTo develop a new drug delivery system is one of the useful approaches to break through the limitation of hydroxycamptothecin (HCPT), a typical DNA topoisomerase I (Topo I) inhibitor in clinical appliance. Injectable glycyrrhizic acid-hydroxycamptothecin (GL-HCPT) micelles that were able to dramatically improve the solubility and stability of HCPT were prepared through self-assembly process and evaluated both ...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Authors: Rezaeian M, Sedaghatkish A, Soltani M Abstract Although intraperitoneal chemotherapy (IPC) has been suggested as a promising method for the management of peritoneal dissemination (PD) of ovarian or colorectal cancers, the actual clinical use of this method has been restricted due to such problems as poor drug penetration into the tumor and high side effects. It is, therefore, necessary to develop new strategies to improve the efficacy of this approach. In the present work, a new strategy is proposed based on intraperitoneal (IP) injection of thermosensitive liposomal doxorubicin (TSL-Dox) with triggered re...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
Conclusion: This case demonstrates the importance of a broad differential diagnosis for a child presenting with leg pain and fever. PMID: 31528139 [PubMed]
Source: Ochsner Journal - Category: General Medicine Tags: Ochsner J Source Type: research
CONCLUSION: Parasitic diseases, such as those caused by Fasciola hepatica, should be kept in mind in the differential diagnosis of primary or metastatic liver tumors, such as colorectal cancer liver metastasis, in patients living in endemic areas. PMID: 31528248 [PubMed]
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
Publication date: Available online 18 September 2019Source: European UrologyAuthor(s): Mary-Ellen Taplin, Emmanueal S. Antonarakis, Karen J. Ferrante, Kerry Horgan, Brent Blumenstein, Fred Saad, Jun Luo, Johann S. de BonoAbstractBackground: Detection of androgen receptor (AR) splice variant-7 (AR-V7) messenger RNA (mRNA) in circulating tumor cells (CTCs) is associated with a suboptimal response to abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Galeterone inhibits CYP17 and AR, and induces AR protein degradation. We hypothesized that galeterone would be clinically superior to enzalu...
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsPeritoneal carcinomatosis of unknown primary site may be caused by an occult appendiceal adenocarcinoma. This error in diagnosis may lead to suboptimal treatment. Surgical exploration to visualize a normal appendix should occur prior to making a definitive diagnosis of peritoneal carcinomatosis of unknown primary site.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Conclusions: Increased NK cells after NAC, together with increased CD4+ and CD8+ T-cells, and decreased CTLA-4+ T cells and VEGF correlate with beneficial therapeutic effects. Systemic activation of pNK cell activity and the presence of pre-NAC TILs may improve the elimination of Ax + together with decreased immunosuppression by VEGF in tumors.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Condition:   Colorectal Adenocarcinoma Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Irinotecan;   Dietary Supplement: Cholecalciferol;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Triple Negative Breast Cancer Interventions:   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Pembrolizumab;   Drug: IL-12 gene therapy;   Drug: L-NMMA Sponsors:   The Methodist Hospital System;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Colorectal Adenocarcinoma Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Irinotecan;   Dietary Supplement: Cholecalciferol;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Neurology | Study | Temodar